U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT06871644) titled 'Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases' on Feb. 27.
Brief Summary: The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
Study Start Date: March 18
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis - ...